Literature DB >> 18785162

Isolation of human embryonic stem cell-derived teratomas for the assessment of pluripotency.

Karin Gertow1, Stefan Przyborski, Jeanne F Loring, Jonathan M Auerbach, Olga Epifano, Timo Otonkoski, Ivan Damjanov, Lars Ahrlund-Richter.   

Abstract

This unit describes protocols on how to assess the developmental potency of human embryonic stem cells (hESCs) by performing xenografting into immunodeficient mice to induce teratoma formation. hESCs can be injected under the testis capsule, or alternatively into the kidney or subcutaneously. Teratomas that develop from grafted hESCs are surgically removed, fixed in formaldehyde, and paraffin embedded. The tissues in the teratoma are analyzed histologically to determine whether the hESCs are pluripotent and form tissues derived from of all three embryonic germ layers (ectoderm, mesoderm, and endoderm). Teratomas can also be fixed in Bouin's or cryosectioned for analysis, and they can be analyzed by immunohistochemistry for tissue markers. Methods for these procedures are included in this unit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18785162     DOI: 10.1002/9780470151808.sc01b04s3

Source DB:  PubMed          Journal:  Curr Protoc Stem Cell Biol        ISSN: 1938-8969


  18 in total

1.  Teratoma formation: a tool for monitoring pluripotency in stem cell research.

Authors:  Raman V Nelakanti; Nigel G Kooreman; Joseph C Wu
Journal:  Curr Protoc Stem Cell Biol       Date:  2015-02-02

2.  Association of telomere length with authentic pluripotency of ES/iPS cells.

Authors:  Junjiu Huang; Fang Wang; Maja Okuka; Na Liu; Guangzhen Ji; Xiaoying Ye; Bingfeng Zuo; Minshu Li; Ping Liang; William W Ge; John Cm Tsibris; David L Keefe; Lin Liu
Journal:  Cell Res       Date:  2011-02-01       Impact factor: 25.617

Review 3.  Current methods and challenges in the comprehensive characterization of human pluripotent stem cells.

Authors:  Joanna S T Asprer; Uma Lakshmipathy
Journal:  Stem Cell Rev Rep       Date:  2015-04       Impact factor: 5.739

4.  Modeling neurological diseases using patient-derived induced pluripotent stem cells.

Authors:  Tarja A Juopperi; Hongjun Song; Guo-Li Ming
Journal:  Future Neurol       Date:  2011-05

5.  Characterization of pluripotent stem cells.

Authors:  Mercè Martí; Lola Mulero; Cristina Pardo; Cristina Morera; Meritxell Carrió; Leopoldo Laricchia-Robbio; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Nat Protoc       Date:  2013-01-10       Impact factor: 13.491

6.  A modified method for implantation of pluripotent stem cells under the rodent kidney capsule.

Authors:  Fuli Zhu; Bin Sun; Yan Wen; Zhe Wang; Renee Reijo Pera; Bertha Chen
Journal:  Stem Cells Dev       Date:  2014-06-24       Impact factor: 3.272

7.  Simplified three-dimensional culture system for long-term expansion of embryonic stem cells.

Authors:  Christina McKee; Mick Perez-Cruet; Ferman Chavez; G Rasul Chaudhry
Journal:  World J Stem Cells       Date:  2015-08-26       Impact factor: 5.326

8.  Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease.

Authors:  Yan Jiang; Sally A Cowley; Ulrich Siler; Dario Melguizo; Katarzyna Tilgner; Cathy Browne; Angus Dewilton; Stefan Przyborski; Gabriele Saretzki; William S James; Reinhard A Seger; Janine Reichenbach; Majlinda Lako; Lyle Armstrong
Journal:  Stem Cells       Date:  2012-04       Impact factor: 6.277

9.  Early events in xenograft development from the human embryonic stem cell line HS181--resemblance with an initial multiple epiblast formation.

Authors:  Karin Gertow; Jessica Cedervall; Seema Jamil; Rouknuddin Ali; Marta P Imreh; Miklos Gulyas; Bengt Sandstedt; Lars Ahrlund-Richter
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

10.  Teratoma generation in the testis capsule.

Authors:  Suzanne E Peterson; Ha T Tran; Ibon Garitaonandia; Sangyoon Han; Kyle S Nickey; Trevor Leonardo; Louise C Laurent; Jeanne F Loring
Journal:  J Vis Exp       Date:  2011-11-07       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.